Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
received:
10
01
2022
accepted:
05
07
2022
pubmed:
17
8
2022
medline:
15
9
2022
entrez:
16
8
2022
Statut:
ppublish
Résumé
Aims of this study are assessing prevalence of anal human papillomavirus (HPV) genotypes in male who have sex with men (MSM) living with HIV over a period of 5 years and determining risk factors for anal infection from high-risk (HR) HPV genotypes or included in vaccine Gardasil 9. Time-trend, monocentric study on MSM living with HIV who underwent HPV test at anal site from 2015 to 2019. Anal swabs were processed by multiplex real-time polymerase chain reaction to detect HPV genotypes. The Cochran-Armitage test was used to assess linear trend in HPV prevalence over time and logistic regression models to estimate risk factors. Of the 1352 MSM living with HIV, 168 (12%) were not infected by any HPV genotypes and only 6 were infected with a maximum of 6 genotypes; prevalence of HR-HPV genotypes or those included in the 9-valent vaccine remained stable over time. At multivariable analysis, the risk of carrying at least 1 genotype classified as HR or included in Gardasil 9 was associated with younger age [adjusted odds ratio (aOR) for younger than 30 years vs older than 45 years (95% confidence interval) 2.714 (1.484 to 4.961), P = 0.001, and 1.868 (1.141 to 3.060), P < 0.013, respectively] and a history of gonorrhea [aOR 2.118 (1.100 to 4.078), P = 0.025, and 1.785 (1.056 to 3.018), P = 0.031, respectively]. Our findings suggest that prevalence remained stable over time and that all MSM with HIV would benefit from Gardasil 9 immunization, particularly the youngest and those with a prior gonococcal infection.
Sections du résumé
BACKGROUND
Aims of this study are assessing prevalence of anal human papillomavirus (HPV) genotypes in male who have sex with men (MSM) living with HIV over a period of 5 years and determining risk factors for anal infection from high-risk (HR) HPV genotypes or included in vaccine Gardasil 9.
SETTING
Time-trend, monocentric study on MSM living with HIV who underwent HPV test at anal site from 2015 to 2019.
METHODS
Anal swabs were processed by multiplex real-time polymerase chain reaction to detect HPV genotypes. The Cochran-Armitage test was used to assess linear trend in HPV prevalence over time and logistic regression models to estimate risk factors.
RESULTS
Of the 1352 MSM living with HIV, 168 (12%) were not infected by any HPV genotypes and only 6 were infected with a maximum of 6 genotypes; prevalence of HR-HPV genotypes or those included in the 9-valent vaccine remained stable over time. At multivariable analysis, the risk of carrying at least 1 genotype classified as HR or included in Gardasil 9 was associated with younger age [adjusted odds ratio (aOR) for younger than 30 years vs older than 45 years (95% confidence interval) 2.714 (1.484 to 4.961), P = 0.001, and 1.868 (1.141 to 3.060), P < 0.013, respectively] and a history of gonorrhea [aOR 2.118 (1.100 to 4.078), P = 0.025, and 1.785 (1.056 to 3.018), P = 0.031, respectively].
CONCLUSION
Our findings suggest that prevalence remained stable over time and that all MSM with HIV would benefit from Gardasil 9 immunization, particularly the youngest and those with a prior gonococcal infection.
Identifiants
pubmed: 35973060
doi: 10.1097/QAI.0000000000003057
pii: 00126334-202210010-00016
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-231Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology . 2010;401:70–79.
Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199:805–814.
Cobos C, Figueroa JA, Mirandola L, et al. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol. 2014;33:383–401.
Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527.
Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer . 2007;121:621–632.
Berrington de Gonzalez A, Sweetland S, Green J. Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. Br J Cancer . 2004;90:1787–1791.
Major Milestone Reached as 100 Countries Have Introduced HPV Vaccine into National Schedule. World Health Organization. Available at: www.who.int/news/item/31-10-2019-major-milestone-reached-as-100-countries-have-introduced-hpv-vaccine-into-national-schedule . Accessed October 11, 2021.
Parisi SG, Basso M, Scaggiante R, et al. Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications. BMC Public Health. 2019;19:645.
Hernandez AL, Karthik R, Sivasubramanian M, et al. Prevalence of anal HPV infection among HIV-positive men who have sex with men in India. J Acquir Immune Defic Syndr. 2016;71:437–443.
Mooij SH, Boot HJ, Speksnijder AG, et al. Six-month incidence and persistence of oral HPV infection in HIV-negative and HIV-infected men who have sex with men. PLoS One . 2014;9:e98955.
Meites E, Gorbach PM, Gratzer B, et al. Monitoring for human papillomavirus vaccine impact among gay, bisexual, and other men who have sex with men-United States, 2012-2014. J Infect Dis. 2016;214:689–696.
Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13:487–500.
Cotte L, Veyer D, Charreau I, et al. Prevalence and Incidence of Human Papillomavirus Infection in Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study: a Sub-study of the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales “Intervention Préventive de l'Exposition aux Risques avec et pour les hommes Gays” Trial. Clin Infect Dis. 2021;72:41–49.
Marra E, King A, van Logchem E, et al. Anal HPV 16 and 18 viral load: a comparison between HIV-negative and -positive MSM and association with persistence. J Med Virol. 2018;90:76–83.
Combes JD, Heard I, Poizot-Martin I, et al. ANRS EP57 APACHES study group. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus-positive men who have sex with men. J Infect Dis. 2018;217:1535–1543.
de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer . 2017;141:664–670.
Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18:198–206.
Schwartz LM, Castle PE, Follansbee S, et al. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. J Infect Dis. 2013;208:1768–1775.
Tugizov S. Human immunodeficiency virus-associated disruption of mucosal barriers and its role in HIV transmission and pathogenesis of HIV/AIDS disease. Tissue Barriers. 2016;4:e1159276.
Papasavvas E, Surrey LF, Glencross DK, et al. High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women. Oncoimmunology. 2016;5:e1128612.
Mbuya W, McHaro R, Mhizde J, et al. Depletion and activation of mucosal CD4 T cells in HIV infected women with HPV-associated lesions of the cervix uteri. PLoS One . 2020;15:e0240154.
Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS . 2018;32:795–808.
Kelly H, Weiss HA, Benavente Y, et al. ART and HPV Review Group. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV . 2018;5:e45-e58.
McCloskey JC, Kast WM, Flexman JP, et al. Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions. Papillomavirus Res. 2017;4:90–98.
Schlecht NF, Masika M, Diaz A, et al. Risk of oral human papillomavirus infection among sexually active female adolescents receiving the quadrivalent vaccine. JAMA Netw open. 2019; 2:e1914031.
Meites E, Winer RL, Newcomb ME, et al. Vaccine effectiveness against prevalent anal and oral human papillomavirus infection among men who have sex with men-United States, 2016-2018. J Infect Dis. 2020; 222, 2052–2060.
Kamolratanakul Supitcha, Pitisuttithum Punnee. Human papillomavirus vaccine efficacy and effectiveness against cancer. Vaccines 2021; 9,12–1413.
Winer RL, Lin J, Querec TD, et al. Effectiveness of human papillomavirus (HPV) vaccination against penile HPV infection in men who have sex with men and transgender women. J Infect Dis. 2022; 225, 422–430.
Drolet M, É Bénard, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565–580.
Ramsey KH, Schneider H, Cross AS, et al. Inflammatory cytokines produced in response to experimental human gonorrhea. J Infect Dis. 1995;172:186–191.
Holly E, Whittemore A, Aston D, et al. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst. 1989;81:1726–1731.
Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine . 2011;29:8443–8450.
Di Ciaccio M, Sagaon-Teyssier L, Mimi M, et al. Changes in sexual behaviors in men who have sex with men: a comparison between the double-blind and open-label extension phases of the ANRS-IPERGAY trial. AIDS Behav. 2020;24:3093–3106.